EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of the COVID ‐19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis

Brian Ng Hung Shin, Samuel Tan, Handoo Rhee, Eric Chung iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Brian Ng Hung Shin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Princess Alexandra Hospital, The University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID‐19 pandemic led to a major disruption to health services across the world. The aim of this population‐based study was to assess the downstream effects of the pandemic on diagnostic tests and treatment activities related to prostate cancer (PC). The Australian Government Department of Health Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme databases were queried from January 2010 to June 2022. Two interrupted time series were performed Pre‐COVID (January 2010 to February 2020) and peri‐COVID (March 2020 to June 2022). Temporal modeling was performed to account for seasonal variation. Pre‐COVID‐19, monthly prostate‐specific antigen (PSA) testing showed a declining trend and testing decreased by 81 tests per 100 000 annually. A single‐month 38% drop in PSA testing was observed in April 2020; this corresponded to Australia's first wave. No change was observed in the rate of prostate biopsies. Peri‐COVID‐19 outbreaks, there was a slight shift toward the use of long‐acting androgen deprivation therapy (ADT) at 4% with a predilection still for short‐acting agents. with no registered change in the overall volume of radiotherapy or surgery. There were no deficits in the number of diagnostic and treatment activities for men with PC. Aside from a slight shift toward long‐acting ADT use during the pandemic, no other patterns were observed. The longer‐term impact such as missed diagnosis or late presentation affecting chances of survival due to COVID‐19 is yet to be ascertained.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCOVID-19AgedMaleHumansProstate-Specific AntigenProstateInterrupted Time Series AnalysisPandemicsAndrogen AntagonistsProstatectomyAustraliaNational Health Programs

Stichwörter der Autor:innen

COVID-19androgensprostatectomyprostatic neoplasmradiationtreatment outcomes

Substanzen

Prostate-Specific AntigenAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Princess Alexandra Hospital, The University of Queensland, Brisbane, QLD, Australia.
  • AndroUrology Centre, Brisbane, QLD, Australia.

ORCID-Profile: Eric Chung

Zitieren

APA

Ng Hung Shin, B., Tan, S., Rhee, H., & Chung, E. (2024). Impact of the COVID ‐19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.34759

Vancouver

Ng Hung Shin B, Tan S, Rhee H, Chung E. Impact of the COVID ‐19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis. International Journal of Cancer. 2024. doi:10.1002/ijc.34759

BibTeX
@article{NgHungShin2024,
  author = {Ng Hung Shin, Brian and Tan, Samuel and Rhee, Handoo and Chung, Eric},
  title = {Impact of the COVID ‐19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34759}
}
Kostenlos starten →